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Background:  We  analyzed  the  impact  of  the  anti-T-cell  agents  basiliximab  and  antithymocyte  globu-
lins  (ATG)  on  antibody  and  cell-mediated  immune  responses  after  inﬂuenza  vaccination  in solid-organ
transplant  recipients.
Methods: 71  kidney  and  heart  transplant  recipients  (basiliximab  [n  = 43]  and  ATG  [n = 28]) received  the
trivalent  inﬂuenza  vaccine.  Antibody  responses  were  measured  at baseline  and  6 weeks  post-vaccination
by  hemagglutination  inhibition  assay;  T-cell  responses  were  measured  by IFN-  ELISpot  assays  and  intra-
cellular cytokine  staining  (ICS);  and  inﬂuenza-speciﬁc  memory  B-cell  (MBC)  responses  were  evaluated
using  ELISpot.
Results:  Median  time  of  vaccination  from  transplantation  was  29  months  (IQR  8–73). Post-vaccination
seroconversion  rates  were  26.8%  for H1N1,  34.1%  for H3N2  and  4.9%  for  inﬂuenza  B in the  basiliximab
group  and  35.7%  for  H1N1,  42.9%  for H3N2  and  14.3%  for inﬂuenza  B in  the  ATG  group  (p = 0.44,  p =  0.61,
and  p  =  0.21,  respectively).  The  number  of  inﬂuenza-speciﬁc  IFN--producing  cells  increased  signiﬁcantly
after  vaccination  (from  35 to 67.5  SFC/106 PBMC,  p = 0.0007),  but  no  differences  between  treatment  groups
were  observed  (p =  0.88).  Median  number  of IgG-MBC  did  not increase  after  vaccination  (H1N1,  p  = 0.94;
H3N2  p = 0.34;  B, p = 0.79),  irrespective  of  the type  of  anti-T-cell  therapy.
Conclusions:  After  inﬂuenza  vaccination,  a signiﬁcant  increase  in  antibody  and  T-cell  immune  responses
but  not  in  MBC  responses  was  observed  in  transplant  recipients.  Immune  responses  were  not  signiﬁcantly
 thatdifferent  between  groupsAbbreviations: ATG, antithymocyte globulins; SOT, solid organ transplant; HI,
emagglutination inhibition; MBC, memory B-cell; ICS, intracellular cytokine stain-
ng; MPA, mycophenolic acid; SFC, spot-forming cells; IL-2, interleukin-2; IFN-,
nterferon-;  TNF-, tumor necrosis factor .
 This work was presented at the World Transplant Congress, San Francisco, July
6th–31st 2014 (abstracts # 1205 and #2876). It was rewarded by a young investi-
ator award.
∗ Corresponding author at: Infection Control, University Hospital and Univer-
ity  of Lausanne, MP18/422, CHUV, Lausanne, Switzerland. Tel.: +41 21 314 1288;
ax: +41 21 31410262.
E-mail address: delphine.hequet@chuv.ch (D. Héquet).
1 Co-senior authorship.
ttp://dx.doi.org/10.1016/j.vaccine.2016.05.021
264-410X/© 2016 Elsevier Ltd. All rights reserved. received  basiliximab  or ATG.
©  2016  Elsevier  Ltd.  All  rights  reserved.
1. Introduction
Inﬂuenza is associated with signiﬁcant morbidity in solid-
organ transplant (SOT) recipients [1,2]. While the main preventive
strategy against inﬂuenza after transplantation remains annual
inﬂuenza vaccination [3], the immunogenicity and efﬁcacy of
inﬂuenza vaccine are suboptimal in this population [4]. This is
mainly due to the use of immunosuppressive drugs to avoid rejec-
tion in transplant recipients, which inhibit mainly T-cell, but also
B-cell, activation. The immunosuppressive regimen usually con-
sists of an induction therapy at time of transplantation, either
basiliximab or antithymocyte globulins (ATG) [5] followed by
maintenance immunosuppression [6]. Basiliximab is a monoclonal
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ntibody that binds the -chain (CD25) of the interleukin 2 recep-
or, inhibiting T-cell activation, but without a depleting effect on
ymphocytes [7]. On the other hand, ATG contains polyclonal IgG
rom rabbits immunized with human thymocytes, which blocks
-cell membrane proteins causing prolonged T-cell depletion [8].
espite lower T-cell counts in patients receiving ATG, humoral
esponses to seasonal inﬂuenza vaccine were similar in kidney
ransplant recipients receiving either ATG or basiliximab as induc-
ion therapy [9].
A signiﬁcant challenge for assessing the efﬁcacy of inﬂuenza
accine is the lack of validated markers of vaccine responses in
mmunocompromised patients. The hemagglutination inhibition
HI) assay correlates with vaccine protection in immunocompe-
ent patients, but it remains unclear whether the HI assay can
redict protection against inﬂuenza in patients receiving immuno-
uppressive drugs, such as in SOT recipients [10–12]. Cell-mediated
mmunity appears to be a promising predictor of vaccine response
13–15]. Induction of T-cell immune responses, mediated by
D4+ and CD8+, is a crucial step for reducing the severity of
ymptoms and for preventing complications of inﬂuenza in the
eneral population [16,17]. Granzyme B levels, a marker for T-cell
esponses, have been correlated with clinical vaccine protection
gainst inﬂuenza in the elderly [16]. Another key component of the
mmune response to inﬂuenza vaccination is antigen-speciﬁc long-
ived plasma cells and memory B-cells (MBC). MBC  are generated
n response to T-dependent antigens and they differentiate into
lasma cells secreting high-afﬁnity antibodies upon re-exposure
o antigen, therefore increasing the effectiveness of the antibody
esponses [18].
There is little information about the impact of immunosuppress-
ve regimens on T-cell and B-cell responses elicited by inﬂuenza
accination. In particular, only few studies have assessed the
nﬂuence of induction therapy on immune responses after organ
ransplantation [19,20]. We  therefore studied humoral, T-cell, and
-cell responses after inﬂuenza vaccination in a prospective cohort
f SOT recipients receiving basiliximab or ATG.
. Materials and methods
.1. Study population and study design
Adult SOT recipients were recruited prospectively from the
utpatient clinic of the Transplantation Center of the University
ospital of Lausanne, Switzerland, during the 2012–2013 inﬂuenza
eason. Patients were included if they were scheduled to receive the
nﬂuenza vaccine, had undergone kidney or heart transplantation
ore than 3 months before vaccination, had received induction
herapy with basiliximab or ATG, and were 18 years or older. The
xclusion criteria were documented egg allergy, an acute febrile ill-
ess within the 7 days preceding vaccination, the occurrence of an
pisode of clinical or biopsy-proven acute rejection 4 weeks before
accination, and previous life-threatening reaction to inﬂuenza
accine. The study was approved by the local institutional review
oard and an informed consent was signed by all the participating
atients.
At enrollment (day 0, pre-vaccination), a baseline blood sam-
le was collected to measure the titers of antibody levels against
ach viral strain, speciﬁc T-cell and B-cell immune responses, as
ell as the CD4+ and CD8+ T-cell counts. Patients then received
 single 0.5 ml  intramuscular injection of the trivalent inﬂuenza
accine in the deltoid muscle of the non-dominant arm. In this
tudy, we used the non-adjuvanted, inactivated trivalent inﬂuenza
accine Mutagrip® (Sanoﬁ-Pasteur MSD, Baar, Switzerland) or
nﬂuvac® (Abbott AG, Switzerland). These vaccines contain
5 g of HA antigen from each viral strain [A/California/7/20094 (2016) 3576–3583 3577
(H1N1)pdm09-like virus, A/Victoria/361/2011 (H3N2)-like virus,
and B/Wisconsin/1/2010-like virus]. At 6 weeks after vaccination,
a second blood sample was collected to measure the humoral and
cellular immune responses to the vaccine. Patients were followed
up for 6 months for the development of inﬂuenza infection and
acute allograft rejection.
2.2. Immunosuppressive protocol
Kidney transplant recipients received per protocol induction
therapy with basiliximab at 20 mg  at days 0 and day 4 post-
transplant. In case of re-transplantation or high immunologic
risk (deﬁned as the presence of anti-HLA antibodies or a panel
reactive antibodies (PRA) of >50%), ATG (Thymoglobulin®, Sanoﬁ
Genzyme, Marcy L’Etoile, France) was  administered at doses of
1–1.5 mg/kg/day for 3–4 days. In case of delayed graft func-
tion [6], basiliximab was discontinued and ATG was  initiated
using the same regimen described above. A daily bolus of intra-
venous methylprednisolone was given during the ﬁrst 3 days after
transplantation. Initial maintenance immunosuppressive ther-
apy consisted of tacrolimus, mycophenolic acid (MPA, either as
mycophenolate mofetil or sodium) and steroids. Heart transplant
recipients received per protocol induction therapy with ATG (same
doses as above) and maintenance therapy with cyclosporine or
tacrolimus, MPA, and steroids. In case of transplantation in patients
with a ventricular assist device implanted pre-transplant, induction
therapy with basiliximab instead of ATG was used.
For the purposes of this study, patients were included in the
ATG group if they have received at least one dose of ATG for (1)
induction therapy or (2) in case of delayed graft function or (3)
for treatment of acute rejection (irrespective of whether they had
previously received basiliximab). All other patients were included
in the basiliximab group.
2.3. Laboratory assays
Total lymphocyte and lymphocyte subpopulation cell counts
were performed at the Laboratory of Immunology, CHUV; Lau-
sanne, Switzerland, using a FacsCalibur ﬂow cytometrer (BD
Bioscience, San Jose, CA, USA).
The hemagglutinin inhibition (HI) assay was  used to analyze
the antibody response and was  performed at the Health Protection
England (HPE) in London, United Kingdom, according to standard-
ized methods [21]. Serum samples were tested with the use of 1:2
serial dilutions at an initial dilution of 1:10. Samples with a negative
result for the hemagglutinin antibody were assigned a titer of 1:5.
Specimens were tested in duplicate, and results were expressed by
the geometric mean titer for analysis.
Peripheral blood mononuclear cells (PBMC) were isolated by
density gradient Ficoll separation. PBMCs were then washed,
counted and frozen in fetal bovine serum (FBS) containing 10%
dimethyl sulfoxide (DMSO) at −80 ◦C overnight and then trans-
ferred to liquid nitrogen until use. Lymphocytes were defrosted and
rested overnight in RPMI medium with 10% fetal calf serum at 37 ◦C.
T-cell responses were assessed by detecting IFN- production, after
stimulation with the 3 viral strains, using a standard ELISpot assay
[22–24]. Brieﬂy, cells (400,000 cells/well) in RPMI medium with
10% fetal calf serum were cultured on a pre-coated IFN- plates
(Mabtech AB, Sweden) with negative control (medium alone) or
inﬂuenza antigens (5 g/ml of split virus vaccine of each inﬂuenza
strain A/H1N1, A/H3N2, B strain). After overnight incubation (37 ◦C,
5% CO2) the assay was developed according to the manufacturer’s
instructions and the plates were read using ImmunoscanTM reader
and associated software (CTL-Europe). Results were expressed as
spot-forming cells (SFC)/106 PBMCs after subtraction of the back-
ground value obtained with non-stimulated cells.
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Intracellular cytokine staining (ICS) was performed to mea-
ure inﬂuenza-speciﬁc CD4 Th1 cytokines interleukin-2 (IL-2) and
umor necrosis factor- (TNF-). PBMC were stimulated overnight
ith a mixture of the three split virus antigens in the vaccine,
/H1N1, A/H3N2 and B (2.5 g/ml of each protein) in the pres-
nce of Brefeldin A, Monensin and anti-CD49d antibodies (BD
iosciences, USA). After ovenight stimulation, cells were stained
or intracellular cytokines and analyzed on a BD LSRFortessa (BD
iosciences) for the expression of IFN-, IL-2 and TNF- from CD4+
-cells [24,25]. CD4+ T cells were classiﬁed on the basis of IFN-,
L-2, and TNF- secretion as single producers (producing any single
ytokine), double producers (2 cytokines), and triple producers (all
 cytokines).
Inﬂuenza-speciﬁc and total IgG memory B-cell responses were
valuated after a 7 day in vitro stimulation using direct inﬂuenza-
peciﬁc ELISpot for each of the three viral strains [26]. Total
gG-MBC responses were measured after being stimulated for 7
ays with Pokeweed mitogen (Sigma) and ODN-2006 (Integrated
NA Technologies). A total of 50,000 cells/well for detection of
nﬂuenza speciﬁc cells were plated for the B-cell ELISpot. The
umber of spots counted varied, but ranged from 0 to 100 spots
er well.
For both T-cell and B-cell ELISpot lymphocytes from a healthy
olunteer were included as a positive control in all assays. The
verage number of SFC for this individual was 487 IFN- SFC/106
BMC (for T-cell ELISpot), 624 IgG-MBC/106 PBMC (for H1N1 MBC
LISpot), 494 IgG-MBC/106 PBMC (for H3N2 MBC  ELISpot), 1156
gG-MBC/106 PBMC (for inﬂuenza B MBC  ELISpot), and 167750 IgG-
BC/106 PBMC (for total IgG-MBC ELISpot).
.4. Clinical deﬁnitions and outcomes
The vaccine induced antibody responses were evaluated accord-
ng to the European Agency for the Evaluation of Medicinal Products
27]. Seroconversion rate was deﬁned as the percentage of patients
ith ≥4-fold increase in antibody titers against inﬂuenza after
accination. Seroprotection rate was deﬁned as the percentage of
atients with an HI after vaccination of 1:40 or more. We  use the
eyer correction to take into consideration the presence of pre-
accination antibodies in the seroconversion rate [28]. We  deﬁned
ntibody vaccine response as corrected seroconversion to at least
ne viral strain. As no correlate of protection has been deﬁned,
esults of the T-cell responses (by IFN- Elispot and by ICS) and
he MBC  responses are shown descriptively.
.5. Statistical analysis
The primary endpoint was the seroconversion rate (serological
esponse with a four-fold or greater increase in HI antibody). With
 planned sample size of 30 patients per group we  expected to have
 power of 80% to detect a difference in the seroconversion rate of
0% between groups (e.g. 50% vs. 80% seroconversion rate in the ATG
roup vs. basiliximab group). Comparisons between the two groups
ere performed by the Fisher’s exact test in case of categorical
ariables, and by the Wilcoxon rank test in case of continuous vari-
bles. The proportion of serological responders (≥ 4-fold increase
n HI antibody titers) between baseline and 6 weeks after vacci-
ation was compared by the Fisher’s exact test. Antibody titers,
FN- SFC counts, ICS data, and IgG SFC counts between pre and
ost-vaccination were compared with the Wilcoxon rank test. The
pearman test was used to correlate humoral and cellular immune
esponses, and T-cell subpopulation counts. All analyses were per-
ormed using GraphPad Prism (GraphPad Software, La Jolla, CA,
SA). Two-tailed p-values <0.05 were considered statistically sig-
iﬁcant.4 (2016) 3576–3583
3. Results
3.1. Baseline characteristics of the study population
A total of 71 patients were enrolled in the study (64 kidney,
5 heart, 1 heart-kidney, and 1 kidney-pancreas recipient) and
received the inﬂuenza vaccine. Overall, 43 patients received basil-
iximab and 28 patients received ATG (14 received only ATG as
induction therapy and 14 received ATG after basiliximab, 12 for
delayed graft function and 2 to treat an episode of acute rejec-
tion). Of note, 66 patients received a subunit virus vaccine and 5
patients a split virus vaccine. Two patients were lost to follow-
up; immunogenicity of the vaccine was therefore assessed in 69
patients. Baseline characteristics are shown in Table 1. The median
of total lymphocyte and CD4+ T-cell counts were signiﬁcantly lower
in patients who  had received ATG induction (909 cells/mm3 and
313 cells/mm3, respectively) as compared to patients who had
received basiliximab (1466 cells/mm3 and 667 cells/mm3, respec-
tively). None of the patients was  diagnosed with inﬂuenza in the
follow-up 6 months after vaccination.
3.2. Antibody response to inﬂuenza vaccine in patients receiving
induction therapy
The HI antibody responses in patients stratiﬁed according to
induction therapy (basiliximab or ATG) are summarized in Table 2.
There was a signiﬁcant increase after vaccination for all three anti-
gens (p < 0.0001 for H1N1, p < 0.0001 for H3N2, and p < 0.0001 for
B). No differences were observed in inﬂuenza H1N1 and H3N2
HI titers between the basiliximab and ATG groups 6 weeks after
vaccination (p = 0.89 for H1N1, and 0.49 for H3N2). The antibody
response against inﬂuenza B was signiﬁcantly higher in ATG group,
in terms of HI titers (10.33 in the basiliximab group vs. 25.92 in
the ATG group, p = 0.007) and in the seroprotection rate (17.1% vs.
50%, respectively, p = 0.007). The Beyer corrected seroconversion
rates were 26.8% for H1N1, 34.1% for H3N2 and 4.9% for inﬂuenza
B in the basiliximab group and 35.7% for H1N1, 42.9% for H3N2
and 14.3% for inﬂuenza B in the ATG group (p = 0.44, p = 0.61, and
p = 0.21, respectively).
We then analyzed other potential clinical variables that inﬂu-
enced antibody response (deﬁned as corrected seroconversion to
at least one viral strain). We  did not ﬁnd any difference in terms of
organ transplanted or immunosuppressive regimen. For example,
vaccine response was 46.2% in patients receiving MPA  as compared
to 52.9% in patients without MPA  (p = 0.78), and 54.1% in patients
receiving tacrolimus as compared to 25% in patients without
tacrolimus (p = 0.15). MPA  dosage did not inﬂuence the seroconver-
sion rate after vaccination (r = −0.17 for H1N1, r = 0.07 for H3N2 and
r = −0.06 for inﬂuenza B). Median time from transplantation was
25.5 months (range 9–73) in responders as compared to 29 months
(range 7–65) in non-responders (p = 0.84). Median CD4+ and CD8+
T-cell counts were 498 (range 321–865) cells/ml and 382 (range
233–612) cells/ml in responders, and 490 (range 259–744) cells/ml
and 348 (range 182–648) cells/ml in non-responders, respectively.
Lower vaccine responses were not observed in patients with pre-
vious allograft rejection (n = 7, data not shown).
3.3. T-cell-mediated immune responses to inﬂuenza vaccine
T-cell-mediated immune responses to inﬂuenza vaccine were
determined by the IFN- ELISpot assay after stimulation with a mix
of the 3 viral strains in 67 patients and by ICS in 51 patients. The
number of patients in whom cell-mediated immunity was assessed
varied according to the number of available cells for each patient.
Table 3 and Fig. 1 show the IFN- response by ELISpot in patients
stratiﬁed according to the induction regimen received (basiliximab
D. Héquet et al. / Vaccine 34 (2016) 3576–3583 3579
Table  1
Baseline characteristics of the study population.
All patients (n = 71) Basiliximab (n = 43) Antithymocyte globulin (n = 28) p-value
Age, median (IQR), yr 54 (46–63) 54 (44–63) 54.5 (47–64.5) 0.62
Gender (M/F) 52/29 28/15 24/4 0.06
Time  from transplant, median (IQR), month 29 (8–73) 31(10–83) 22 (6.25–56.75) 0.23
Organ  transplanted; n (%)
- Kidney 64 (90.2) 40 (93) 24 (85.7) 0.4
-  Heart 5 (7) 3 (7) 2 (7.1) 1.00
-  Heart–kidney 1 (1.4) 0 1 (3.6) 1.00
-  Kidney–pancreas 1 (1.4) 0 1 (3.6) 1.00
Underlying disease; n (%)
Kidney transplant recipients (n = 66)a n = 40 n = 26
-  ADPKD 11 (16.7) 7(17.5) 4 (15.4) 1.00
-  Berger disease 9 (13.6) 6 (15) 3 (11.5) 1.00
-  Reﬂux disease 7 (10.6) 5 (12.5) 2 (7.7) 0.69
-  Alport disease 6 (9.1) 4 (10) 1 (3.8) 0.64
-  Hypertensive nephropathy 5 (7.6) 2 (5) 4 (15.4) 0.20
-  Other 28 (42.4) 16 (40) 12 (46.2) 0.79
Heart  transplant recipients (n = 6)b n = 3 n = 3 1.00
-  Ischemic 3 (50) 2 (66.7) 1 (33.3)
-  Hypertrophic cardiomyopathy 1 (16.6) 0 1 (33.3)
-  Dilated cardiomyopathy 1 (16.6) 0 1 (33.3)
-  Genetic disorder 1 (16.6) 1 (33.3) 0
Previous transplantation, n (%) 11 (15.5) 7 (16.3) 4 (14.3) 1.00
Maintenance immunosuppresion, n (%)
-  Prednisone 48 (67.6) 26 (60.5) 22 (78.6) 0.12
-  Tacrolimus 63 (88.7) 36 (83.7) 27 (97.4) 0.13
-  Cyclosporine 7 (9.9) 7 (16.3) 0 0.0001
-  mTOR inhibitor 1 (1.4) 0 1 (3.6) 0.39
-  MPA  53 (74.6) 33 (76.7) 20 (71.4) 0.78
-  Azathioprine 12 (16.9) 8 (18.6) 4 (9.3) 0.75
Allograft rejection before vaccination, n (%) 7 (9.8) 5 (11.6) 2 (7.1) 0.69
-  Acute cellular rejection 5 (7.0) 3 (7.0) 2 (7.1) 1.00
-  Chronic humoral rejection 2 (2.8) 2 (4.6) 0 0.51
Rituximab treatment, n (%) 2 (2.8) 0 2 (7.1) 0.15
2011–2012 inﬂuenza vaccine, n (%) 61 (85.9) 38(88.4) 23 (82.1) 0.5
Creatinine level, median (IQR), M/l  133 (69–154) 129 (103–147) 138.5 (103–152) 0.31
Leucocyte count, median (IQR), cells/mm3
- Total lymphocytes 1251 (259–1773) 1466 (959–2216) 909 (621.8–1533) 0.002
-  CD4+ lymphocytes. 497 (299–1670) 667 (497–914) 313 (200.5–389.5) <0.0001
-  CD8+ lymphocytes 380 (229–1654) 410 (268–701) 248 (191–500.5) 0.05
ADPKD: autosomal dominant polycystic kidney disease, MPA: mycophenolic acid.
a Including kidney, kidney–pancreas, and heart–kidney transplant recipients.
b Including heart and heart kidney transplant recipients.
Table 2
Antibody response by hemagglutination inhibition assay before and after inﬂuenza vaccination for each viral strain according to induction therapy.
All patients (n = 69) Basiliximab (n = 41) Antithymocyte globulin (n = 28) p-value
Geometric mean titer (95% CI)
• Week 0
Inﬂuenza A H1N1 30.79 (21.3–44.52) 28.76 (18.03–45.87) 34.03 (18.05–64.15) 0.72
Inﬂuenza A H3N2 107.6 (92.27–125.5) 98.87 (80.46–121.5) 121.9 (96.06–154.6) 0.16
Inﬂuenza B 9.65 (7.58–12.28) 7.56 (6.07–9.41) 13.8 (8.45–22.51) 0.07
•  Week 6
Inﬂuenza A H1N1 54.88 (39.03–77.17)* 53.77 (35.36–81.76)* 56.55 (30.79–103.8)* 0.89
Inﬂuenza A H3N2 157 (134.7–182.9)* 147.1 (122.3–176.8)* 172.7 (131.2–227.3)* 0.49
Inﬂuenza B 15.01 (11.09–20.30)* 10.33 (7.67–13.91)* 25.92 (14.68–45.78)* 0.007
Seroprotection rate, n (%)
• Week 0
Inﬂuenza A H1N1 32 (46.4) 19 (46.3) 13 (46.4) 1.00
Inﬂuenza A H3N2 67 (97.1) 39 (95.1) 28 (100) 0.51
Inﬂuenza B 13 (18.8) 3 (7.3) 10 (35.7) 0.03
•  Week 6
Inﬂuenza A H1N1 42 (60.9) 26 (63.4) 16 (57.1) 0.80
Inﬂuenza A H3N2 69 (100) 41 (100) 28 (100) 1.00
Inﬂuenza B 21 (30.4) 7 (17.1) 14 (50) 0.007
Seroconversion rate, n (%)
Inﬂuenza A H1N1 13 (18.8) 10 (24.4) 3 (10.7) 0.21
Inﬂuenza A H3N2 2 (2.9) 2 (4.9) 0 (0) 0.51
Inﬂuenza B 11 (15.9) 4 (9.8) 7 (25) 0.10
Beyer  corrected seroconversion rate, n (%)
Inﬂuenza A H1N1 21 (30.4) 11 (26.8) 10 (35.7)
Inﬂuenza A H3N2 26 (37.7) 14 (34.1) 12 (42.9) 0.44
Inﬂuenza B 6 (8.7) 2 (4.9) 4 (14.3) 0.61
* p < 0.001 between before and after vaccination for all three viral strains.
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Table 3
T-cell-mediated immune response by IFN- secretion before and after inﬂuenza vaccination after stimulation with all three viral strains.
All patients (n = 67) Basiliximab (n = 40) Antithymocyte globulin (n = 27) p-value
IFN- median SFC (IQR), SFC/106 PBMC
•  Week 0 35 (11.3–81.3) 43.1 (10.3–81.3) 32.5 (12.5–73.8) 0.59
•  Week 6 67.5 (27.5–131.3)* 66.9 (27.5–132.8)
*p = 0.0007, **p  = 0.05, ***p = 0.004 before and after vaccination.
Fig. 1. T-cell immune response, evaluated by IFN- secretion (ELISPOT), according
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lack and data after vaccination are represented in gray. Each dot represents one
ndividual and bars show the median.
n = 40] or ATG [n = 27]). While IFN- secretion increased in both
roups six weeks after vaccination (p = 0.05 for the basiliximab
roup and 0.004 for the ATG group), the differences between the
wo groups were not statistically signiﬁcant. The use of a partic-
lar drug for maintenance immunosuppression did not inﬂuence
he IFN- secretion after vaccination (data not shown). In partic-
lar, differences in T cell-mediated immune responses were not
bserved according to the dose of MPA  received.
Fig. 2A shows the frequencies of inﬂuenza-speciﬁc CD4+ T-
ells secreting either a single Th1 cytokine (IFN-, TNF-, or IL-2)
r simultaneously producing more than one cytokine (multifunc-
ional cells) before and after vaccination in all 51 patients. The
ercentage of IFN- (p = 0.01) and TNF- (p = 0.006) single-cytokine
roducing cells was signiﬁcantly higher after vaccination compared
ith pre-vaccination levels, as well as the percentage of multi-
unctional T-cells, with a signiﬁcant increase in cells producing
ig. 2. Inﬂuenza speciﬁc CD4+T-cell response following inﬂuenza vaccination. PBMCs w
requency of CD4+ cells producing interleukin-2 (IL-2), interferon- (IFN-) and tumor ne
peciﬁc  CD4+ cells before vaccination is shown in black and data after vaccination are rep** 76.3 (27.5–131.3)*** 0.88
2 cytokines (IL-2+TNF-+, p = 0.02) and all 3 cytokines (IFN-+
IL-2+ TNF-+, p = 0.01). When we  looked at the multifunctional
CD4+ T cell responses in the basiliximab [n = 30] and the ATG
[n = 21] groups, we  observed a higher percentage of speciﬁc CD4+
T-cells expressing all three cytokines in the ATG group (median of
0.021%), as compared to in the basiliximab group (median of 0.010%,
p = 0.14), although the differences were not statistically signiﬁcant
(Fig. 2B).
3.4. B-cell-mediated immune responses to inﬂuenza vaccine
We  then assessed the total and inﬂuenza MBC responses by
ELISpot in 64 patients. Overall, no signiﬁcant increase in the median
number of IgG-MBC/106 PBMC was  observed against any of the
three viral strains (H1N1, p = 0.94; H3N2, p = 0.34; inﬂuenza B,
p = 0.79) (Fig. 3A). The total IgG MBC  responses did not increase
after vaccination either (p = 0.19) (Fig. 3B).
MBC  responses were assessed in 38 patients in the basiliximab
group and 26 patients in the ATG group (Fig. 4). IgG-MBC/106 PMBC
levels after vaccination were generally lower in the ATG group
as compared to the basiliximab group for each of the three viral
strains, although these differences were not statistically signiﬁcant.
The post-vaccination total IgG responses were signiﬁcantly lower in
the ATG group compared with the group that received basiliximab
(6327 vs. 11905 IgG-MBC/106 PBMC, p = 0.05).
The B-cell responses were not inﬂuenced by the maintenance
immunosuppressive regimen received (data not shown). However,
we observed a positive correlation between CD4+ T-cell count and
inﬂuenza A H1N1 IgG MBC  response (r = 0.34 and p = 0.005) and
with total IgG MBC  response (r = 0.31 and p = 0.01) (Supplementary
Fig. 1). We  also assessed the inﬂuence of inﬂuenza vaccination on
the previous year on MBC  responses. MBC  responses were not sta-
tistically different in patients with or without previous inﬂuenza
vaccination (30 vs. 0 for H1N1 [p = 0.37], 40 vs. 5 for H3N2 [p = 0.24],
and 60 vs. 15 for B [p = 0.64], respectively).
ere isolated and stimulated with a mix of the three viral strains to measure the
crosis factor  (TNF-)  by multiparametric ﬂow cytometry (ICS). The percentage of
resented in gray. Each dot represents one individual and bars show the median.
D. Héquet et al. / Vaccine 34 (2016) 3576–3583 3581
F uclea
p al IgG 
d
3
w
s
s
F
b
(
Mig. 3. Memory B cell responses after inﬂuenza vaccination. Peripheral blood monon
erformed to measure inﬂuenza-speciﬁc IgG response for each viral strain (A) or tot
ata  in gray. Each dot represents one individual and bars show the median.
.5. Correlation between humoral and cellular responses
We  assessed the T-cell and B-cell immune responses in patients
ith or without an antibody response to each of the three inﬂuenza
trains (Supplementary Table 1). Overall, we did not observe any
igniﬁcant differences between antibody vaccine responders and
ig. 4. MBC  immune response according to induction therapy (basiliximab or ATG). Peri
efore an Elispot assay was performed to measure inﬂuenza-speciﬁc IgG response for eac
basiliximab or ATG). The pre-vaccination data are shown in black and the post-vaccinat
ann–Whitney test was performed to attest of the statistical signiﬁcance.r cells were stimulated in vitro with mitogens for 6 days before an Elispot assay was
response (B). The pre-vaccination data are shown in black and the post-vaccination
non-responders in terms of IFN- median SFC, percentage of mul-
tifunctional speciﬁc CD4+ T cells, and speciﬁc IgG MBC  responses for
any of the three viral strains. Correlation between antibody titers
and number of IgG SFC for each of the viral strains showed only
weak non-signiﬁcant correlation with the H3N2 strain, but not with
the other strains (Supplementary Fig. 2).
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.6. Inﬂuence of time from transplantation to vaccination on
mmune responses
Overall, 22 patients were transplanted in the year preceding
accination; 11 in the ATG group and 11 in the basiliximab group.
ata on humoral and T-cell responses were available for 21 patients
11 ATG and 10 basiliximab). The Beyer corrected seroconversion
ates were 45.5% for H1N1, 36.4% for H3N2 and 18.2% for inﬂuenza
 in the ATG group and 40% for H1N1, 50% for H3N2 and 0% for
nﬂuenza B in the basiliximab group (p = 0.87, p = 0.38, and p = 0.39,
espectively). No difference was seen in median IFN- secretion
 weeks after vaccination (60.0 SFC/106 PBMC for ATG and 60.6
FC/106 PBMC for basiliximab [p = 0.84]). Regarding B-cell immune
esponse analysis, data was available for 19 patients (10 in ATG and
 basiliximab). Median IgG-MBC/106 PBMC were 5 for H1N1, 0 for
3N2 and 15 for inﬂuenza B in the ATG group and 10 for H1N1, 40
or H3N2 and 70 for inﬂuenza B in the basiliximab group (p = 0.91,
 = 0.31, and p = 0.54, respectively).
. Discussion
In this cohort of SOT recipients we assessed the humoral and
ellular immune responses after inﬂuenza vaccination in patients
eceiving two different types of anti T-cell therapies. We  did not
bserved any signiﬁcant difference between both therapies in
erms of humoral, T-cell, and B-cell mediated immunity against
nﬂuenza, independently of the time from transplant and other clin-
cal parameters. A signiﬁcant result of the study is the ﬁnding that
nﬂuenza vaccination elicited rather appropriate antibody and T-
ell responses. Also, we observed a poor memory B-cell response
o the vaccine that was not correlated with previous use of the
nﬂuenza vaccine.
According to previous studies, the immunogenicity of inﬂuenza
accine is reduced in SOT recipients, with up to 15–70% of
atients failing to respond to the vaccine, depending on the organ
ransplanted, the immunosuppressive regimen, and the time of
accination after transplant [29–33]. In our study, previous admin-
stration of induction therapy had no impact on the inﬂuenza
accine response (humoral and cellular) even though the CD4+ cell
ount was lower in the group that had received ATG. The simi-
ar antibody responses observed are in keeping with our previous
tudy, where lymphocyte-depleting antibodies did not inﬂuence
he antibody response to inﬂuenza vaccination [9]. This can be par-
ially explained by the fact that we included stable SOT recipients,
everal months after transplantation, in whom the impact of a par-
icular immunosuppressive drug could have been less evident than
ust after transplantation.
We  observed a high seroprotection rate and a low seroconver-
ion rate in our population, independent of the induction therapy
eceived. This is most likely due to a high number of patients hav-
ng detectable antibodies pre-vaccination, reﬂecting previous use
f inﬂuenza vaccine in our patient cohort [30,34,35]. After taking
nto consideration the pre-vaccination titers [28], seroconversion
ates increased up to 32–38% for inﬂuenza A strains, a rate near of
he 40% seroconversion rate which is considered as appropriate for
he general population [9,36].
Speciﬁc T-cell and B-cell responses have also been implicated in
rotection against inﬂuenza [16]. However, characteristics of the
ellular immune response to inﬂuenza vaccine in immunocompro-
ised patients, such in SOT recipients [4,23,37,38] are not widely
eported. Because of lower CD4+ T-cell counts, we  expected lower
nﬂuenza speciﬁc T-cell mediated responses in patients receiving
TG, but this was not observed in our study. This can be par-
ially explained by a lack of correlation between absolute CD4+
ell counts and the functional activity of these cells after antigenic4 (2016) 3576–3583
stimulation. For example, in a cohort of kidney transplant recipi-
ents, the use of ATG was associated with the development of severe
infections late after transplantation only in patients with impaired
T-cell proliferation, but this was independent on the absolute num-
bers of CD4+ cells. Also, CD4+ cell counts were not associated with
Il-2 expression or CD4 helper activity, supporting our data of an
appropriate multifunctional speciﬁc T-cell response to inﬂuenza
vaccine in patients with low CD4+ cell counts [7,39].
B-cell responses after inﬂuenza vaccination in immunocompro-
mised patients have been insufﬁciently reported. In a prospective
study involving 64 HIV-infected individuals, inﬂuenza vaccination
elicited a poor MBC  response, as compared to healthy volunteers.
CD4+ T cell count in HIV-infected individuals was  a critical determi-
nant of this response [26]. These results agree with our study, where
the MBC  response was not enhanced after vaccination and was  cor-
related with the CD4+ T-cell count. Interestingly, the baseline MBC
response observed in this study was generally lower than what
we observed in a cohort of healthcare workers [40]. It is unclear
why the SOT recipients elicited a weak baseline MBC  response, but
previous studies identiﬁed the use of MPA  as a responsible for a
reduced HLA-DR expression on B cells after inﬂuenza vaccination
[41]. Defective MBC  responses were not observed in other studies
including stable kidney transplant recipients [42] and HIV-infected
children vaccinated against inﬂuenza [43].
One of the limitation of our study is that we did not include a con-
trol group of healthy volunteers or a group of transplant recipients
that did not receive any induction therapy (at our center all patients
receive induction therapy as per protocol) to compare the breadth
of the vaccine immune responses; however, humoral and T-cell
responses were consistent with those observed in previous stud-
ies in SOT recipients, and met  the recommendations of European
authorities. Also, we included a somewhat heterogeneous popula-
tion in terms of transplant type and immunosuppressive regimens;
we did not observe however differences in vaccine responses
according to any speciﬁc drug. This could be also explained by the
relatively modest sample size of our study. While we  only eval-
uated one single time-point after vaccination, previous work has
showed that a signiﬁcant increase in blood MBC  levels was  observed
between 27–42 days after inﬂuenza vaccination in healthy adults
[40,44].
In conclusion, our study showed that vaccination can induce
inﬂuenza-speciﬁc humoral and T-cellular immunity in most kidney
and heart transplant recipients. No correlation was found between
humoral and cell-mediated immunity and no clinical factor inﬂu-
encing this response was identiﬁed. Because most patients were
vaccinated years after transplant, the vaccine responses observed
in our study might not be representative of all SOT recipients.
More work will be necessary to further analyze this defective MBC
response in transplant recipients.
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